Guerbet LLC

 Guerbet LLC, the U.S. subsidiary, was established in January of 2002 by purchasing the assets of Oxilan® (ioxilan) Injection from Cook, one of the leaders in the device industry.

Currently, Guerbet LLC is responsible for the marketing, sales, and distribution of the first macrocyclic and ionic gadolinium-based contrast in the USA, Dotarem® (gadoterate meglumine) Injection, the only oil-based based contrast agent currently available in the USA, Lipiodol® (ethiodized oil) Injection, the only low-osmolar, low-viscosity dimer currently available in the USA, Hexabrix® (ioxaglate meglumine 39.3% and ioxaglate sodium 19.6%) Injection, and the low-osmolar x-ray contrast media Oxilan®.  

Guerbet LLC headquarters is located in Princeton, NJ.

Dotarem® Full Prescribing Information Read more
Lipiodol® Full Prescribing Information Read more
Hexabrix® Full Prescribing Information Read more
Oxilan® Full Prescribing Information Read more